Drug intelligence / Profile preview

[18F]MNI-952

Development stage
Phase 1
Lead developer
Invicro
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Parenteral, Injection (intravenous)
01

Overview

[18F]MNI-952 is a radiopharmaceutical diagnostic agent developed as a positron emission tomography (PET) radioligand for imaging tau protein aggregates in the brain. It is designed to enhance PET imaging by selectively binding to microtubule-associated protein tau, which accumulates abnormally in neurodegenerative diseases such as Alzheimer's disease and progressive supranuclear palsy. The compound contains the radioactive isotope fluorine-18 ([^18F]), enabling visualization of tau pathology in vivo. Its primary use is investigational, aimed at aiding diagnosis and research into tauopathies by providing detailed images of tau distribution and burden within the central nervous system[1][2][4].

Other names
[18F]MNI 952[18F]UCB-K18F-UCB-K
02

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on [18F]MNI-952.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]MNI-952.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call